Top-Rated StocksTop-RatedNASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $23.05 -0.16 (-0.69%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nurix Therapeutics alerts: Email Address About Nurix Therapeutics Stock (NASDAQ:NRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$23.02▼$23.5550-Day Range$20.01▼$25.6952-Week Range$4.22▼$26.31Volume225,187 shsAverage Volume891,229 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$27.00Consensus RatingModerate Buy Company OverviewNurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More… 10X More Profitable Than Physical Gold? (Ad)The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIMES bigger gains than physical gold. That's why I've put together a special presentation on this opportunity...you can access it right here. Nurix Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks39th Percentile Overall ScoreNRIX MarketRank™: Nurix Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 766th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.95) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 5.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.04% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.04% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment1.00 News SentimentNurix Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nurix Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,416,751.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Stock News HeadlinesNurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Christine Ring Sells 9,050 SharesSeptember 5, 2024 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Stock Price Down 5.7%September 25 at 6:07 PM | americanbankingnews.comThe Standard Oil of AI?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...September 28, 2024 | Behind the Markets (Ad)Nurix Therapeutics (NASDAQ:NRIX) Hits New 12-Month High at $26.26September 20, 2024 | americanbankingnews.comNurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering SummitSeptember 6, 2024 | globenewswire.comNurix Therapeutics (NASDAQ:NRIX) Stock, Short Interest ReportSeptember 5, 2024 | benzinga.comNurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right NowSeptember 5, 2024 | msn.comNurix Therapeutics to Participate in Upcoming Investor ConferencesAugust 29, 2024 | globenewswire.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $10.32 on January 1st, 2024. Since then, NRIX stock has increased by 123.4% and is now trading at $23.05. View the best growth stocks for 2024 here. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) released its quarterly earnings results on Thursday, July, 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. The company had revenue of $12.09 million for the quarter, compared to analysts' expectations of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative trailing twelve-month return on equity of 67.78%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Nurix Therapeutics' top institutional investors include ARK Investment Management LLC (3.61%), Driehaus Capital Management LLC (2.61%), Candriam S.C.A. (2.37%) and Affinity Asset Advisors LLC (1.86%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND) and Delta Air Lines (DAL). Company Calendar Last Earnings7/11/2024Today9/27/2024Next Earnings (Estimated)10/10/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$36.00 Low Stock Price Target$10.00 Potential Upside/Downside+17.1%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,950,000.00 Net Margins-264.84% Pretax Margin-264.55% Return on Equity-67.78% Return on Assets-44.37% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$62.30 million Price / Sales18.18 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book5.58Miscellaneous Outstanding Shares49,151,000Free Float45,612,000Market Cap$1.13 billion OptionableOptionable Beta2.23 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NRIX) was last updated on 9/28/2024 by MarketBeat.com Staff From Our PartnersThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | Sponsored10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredFed Triggers Boom: Buy this Play on Elon’s New AIHave you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...InvestorPlace | Sponsored50-Yr Wall Street Legend: “Sell this AI stock NOW”Nearly 1 million people around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly ...Chaikin Analytics | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.